Astria shareholders approve BioCryst acquisition
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- Wall St futures tick higher as oil retreats ahead of inflation data
- Oil falls on weaker demand outlook and higher US stocks
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- CoreWeave soars after fifth straight quarter of record revenue, raised guide
- After-Hours Movers: CSCO, COHR, HLIT, CBRS, STUB, ENS
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
Astria Stockholders Vote to Approve Acquisition by BioCryst
January 21, 2026 4:00 PM ESTBOSTON--(BUSINESS WIRE)-- Astria Therapeutics, Inc. (Nasdaq: ATXS) today announced that at the special meeting of Astrias stockholders held on January 21, 2026, Astrias stockholders voted to approve the acquisition of Astria by BioCryst Pharmaceuticals, Inc. (the Merger).
The parties expect the Merger to close on or about January 23, 2026, subject to the satisfaction of customary closing conditions.
About Astria Therapeutics
Astria Therapeutics is a biopharmaceutical company, whose mission is to bring life-changing therapies to patients and families affected by allergic and immunologic diseases. Astria's lead program, navenibart (STAR-0215), is a monoclonal... More
